# BUTORPHANOL- butorphanol tartrate injection, solution Patterson Veterinary

-----

## ANADA # 200-332, Approved by FDA

## Butorphanol CIV (butorphanol tartrate injection)


## CAUTION

Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian

## DESCRIPTION

Butorphanol (butorphanol tartrate) Injection is a totally synthetic centrally acting, narcotic agonistantagonist analgesic with potent antitussive activity. It is a member of the phenanthrene series. The chemical name is Morphinan-3, 14-diol, 17-(cyclobutylmethyl)-,(-)-, (S-(R\*,R\*))-2,3dihydroxybutanedioate (1:1) (salt). It is a white, crystalline, water soluble substance having a molecular weight of 477.55; its molecular formula is C21H29NO2•C4H6O6.

## **Chemical Structure:**



Each mL of Butorphanol Injection contains butorphanol base (as butorphanol tartrate, USP) 10 mg, 3.3 mg citric acid, USP, 6.4 mg sodium citrate, USP, 4.7 mg sodium chloride, USP, and 0.1 mg benzethonium chloride, USP, q.s. with water for injection, USP.

## CLINICAL PHARMACOLOGY

## **Comparative Pharmacology**

In animals, butorphanol has been demonstrated to be 4 to 30 times more potent than morphine and pentazocine (Talwin<sup>®</sup>-V) respectively.<sup>1</sup> In humans, butorphanol has been shown to have 5 to 7 times the analgesic activity of morphine and 20 times that of pentazocine.<sup>2,3</sup> Butorphanol has 15 to 20 times the oral antitussive activity of codeine or dextromethorphan in dogs and guinea pigs.<sup>4</sup>

As an antagonist, butorphanol is approximately equivalent to nalorphine and 30 times more potent than pentazocine.<sup>1</sup>

Cardiopulmonary depressant effects are minimal after treatment with butorphanol as demonstrated in dogs,<sup>5</sup> humans<sup>6,7</sup> and horses.<sup>8</sup> Unlike classical narcotic agonist analgesics which are associated with decreases in blood pressure, reduction in heart rate, and concomitant release of histamine, butorphanol does not cause histamine release.<sup>1</sup> Furthermore, the cardiopulmonary effects of butorphanol are not distinctly dosage related but rather reach a ceiling effect beyond which further dosage increases result in relatively lesser effects.

Reproduction: Studies performed in mice and rabbits revealed no evidence of impaired fertility or harm to the fetus due to butorphanol tartrate. In the female rat, parenteral administration was associated with increased nervousness and decreased care for the newborn, resulting in a decreased survival rate of the

newborn. This nervousness was seen only in the rat species.


# **Equine Pharmacology**

Following intravenous injection in horses, but orphanol is largely eliminated from the blood within 3 to 4 hours. The drug is extensively metabolized in the liver and excreted in the urine.

In ponies, butorphanol given intramuscularly at a dosage of 0.22 mg/kg was shown to alleviate experimentally induced visceral pain for about 4 hours.<sup>9</sup>

In horses, intravenous dosages of butorphanol ranging from 0.05 to 0.4 mg/kg were shown to be effective in alleviating visceral and superficial pain for at least four hours, as illustrated in the following figure:

## Analgesic Effects of Butorphanol Given at Various Dosages in Horses with Abdominal Pain



\*Pain threshold in butorphanol-treated colicky horses relative to placebo controls

A definite dosage-response relationship was detected in that butorphanol dosage of 0.1 mg/kg was more effective than 0.05 mg/kg but not different from 0.2 mg/kg in alleviating deep abdominal pain.

# Acute Equine Studies

Rapid intravenous administration of butorphanol at a dosage of 2.0 mg/kg (20 times the recommended dosage) to a previously unmedicated horse resulted in a brief episode of inability to stand, muscle fasciculation, a convulsive seizure of 6 seconds duration, and recovery within three minutes. The same dosage administered after 10 successive daily 1.0 mg/kg dosages of butorphanol resulted only in transient sedative effects. During the 10 day course of administration at 1.0 mg/kg (10 times the recommended use level) in two horses, the only detectable drug effects were transient behavioral changes typical of narcotic agonist activity. These included muscle fasciculation about the head and neck, dysphoria, lateral nystagmus, ataxia, and salivation. Repeated administration of butorphanol at 1.0 mg/kg (10 times the recommended dose) every four hours for 48 hours caused constipation in one of two horses.

# Subacute Equine Studies

Horses were found to tolerate butorphanol given intravenously at dosages of 0.1, 0.3, and 0.5 mg/kg every 4 hours for 48 hours followed by once daily injections for a total of 21 days. The only detectable drug effects were slight transient ataxia observed occasionally in the high dosage group. No clinical, laboratory, or gross or histopathologic evidence of any butorphanol-related toxicity was encountered in the horses.

# INDICATIONS

Butorphanol (butorphanol tartrate) Injection is indicated for the relief of pain associated with colic in adult horses and yearlings. Clinical studies in the horse have shown that butorphanol tartrate alleviates

abdominal pain, associated with torsion, impaction, intussusception, spasmodic and tympanic colic, and postpartum pain.

# WARNINGS

## DO NOT USE IN HORSES INTENDED FOR HUMAN CONSUMPTION.

## CAUTION

Butorphanol Injection, a potent analgesic, should be used with caution with other sedative or analgesic drugs as these are likely to produce additive effects.

There are no well-controlled studies using butorphanol in breeding horses, weanlings, and foals. Therefore, the drug should not be used in these groups.

## **ADVERSE REACTIONS**

In clinical trials in horses, the most commonly observed side effect was slight ataxia which lasted 3 to 10 minutes. Marked ataxia was reported in 1.5% of the 327 horses treated. Mild sedation was reported in 9% of the horses.

## DOSAGE

The recommended dosage in the horse is 0.1 mg of butorphanol per kilogram of body weight (0.05 mg/lb) by intravenous injection. This is equivalent to 5 mL of Butorphic Injection for each 1000 lbs body weight. The dose may be repeated within 3 to 4 hours but treatment should not exceed 48 hours. Pre-clinical model studies and clinical field trials in horses demonstrate that the analgesic effects of butorphanol tartrate are seen within 15 minutes following injection and persist for about 4 hours.

## HOW SUPPLIED

Butorphanol (butorphanol tartrate) Injection, 10 mg base activity per mL.

NDC 14043-701-20	20 mL vial in package of one
NDC 14043-701-50	50 mL vial in package of one

## STORAGE

Store at controlled room temperature 20° to 25°C (68° to 77°F). Protect from light.

## REFERENCES

- 1. Pircio. A.W. *et al*: The Pharmacology of Butorphanol. *Arch. Int. Pharmacodyn. Ther.* 220(2):231-257, 1976.
- 2. Dobkin, A.B. *et al*: Butorphanol and Pentazocine in Patients with Severe Postoperative Pain. *Clin. Pharmacol. Ther* 18:547-553, 1975.
- 3. Gilbert, M.S. *et al*: Intramuscular Butorphanol and Meperidine in Postoperative Pain. *Clin. Pharmacol. Ther.* 20:359-364, 1976.
- 4. Cavanagh, R.L. *et al*: Antitussive Properties of Butorphanol, *Arch. Int. Pharmacodyn. Ther.* 220 258-268, 1976.
- 5. Shurig, J.E. *et al*: Effect of Butorphanol and Morphine on Pulmonary Mechanics, Arterial Blood Pressure, and Venous Plasma Histamine in the Anesthetized Dog. *Arch. Int. Pharmacodyn. Ther.* 233:296-304, 1978.
- 6. Nagashmina, H. *et al:* Respiratory and Circulatory Effects of Intravenous Butorphanol and Morphine *Clin. Pharmacol. Ther.* 19:735-745, 1976.

- 7. Popio, K.A. *et al*. Hemodynamic and Respiratory Effects of Morphine and Butorphanol. *Clin. Pharm. Ther.* 23:281-287, 1978.
- 8. Robertson, J.T. and Muir, W.W.: Cardiopulmonary Effects of Butorphanol Tartrate in Horses. *Am. J. Vet. Res.* 42:41-44, 1981.
- 9. Kalpravidh, M. *et al*: Effects of Butorphanol, Flunixin, Levorphanol, Morphine, Pentazocine and Xylazine in Ponies. *Am. J. Vet. Res.* 45:217-223, 1984.

## PATTERSON<sup>®</sup> VETERINARY

#### **Manufactured for:**

Patterson Veterinary, 822 7th Street, Suite 740, Greeley, CO 80631 www.pattersonvet.com

PBU00N Rev. 07/17

Principal Display Panel Text for Container Label:

NDC 14043-701-20

PATTERSON®

VETERINARY Logo

Butorphanol CIV

(butorphanol tartrate injection)

contains 10 mg butorphanol base

per mL as butorphanol tartrate, USP

Caution: Federal (USA) law restricts this drug to use by

or on the order of a licensed veterinarian.

ANADA 200-332, Approved by FDA

20 mL



Principal Display Panel Text for Carton Label: NDC 14043-701-20 PATTERSON<sup>®</sup> VETERINARY Logo Butorphanol CIV (butorphanol tartrate injection) contains 10 mg butorphanol base per mL as butorphanol tartrate, USP **Caution:** Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian. ANADA 200-332, Approved by FDA



Active ingreulent/	Active Moiety					
Ingredient Name			Basis	of Strength	Strength	
Butorphanol Tartrate (UNII: 2L7I72RUHN) (Butorphanol - UNII:QV897JC36D)		Butorpha	anol Tartrate	10 mg in 1 mL		
Inactive Ingredien	its					
Ingredient Name					Strength	
Citric Acid Monohydra	te (UNII: 2968PHW8QP)				-	
Sodium Citrate (UNII: 1	Q73Q2JULR)					
Sodium Chloride (UNII	: 451W47IQ8X)					
Benzethonium Chlorid	<b>e</b> (UNII: PH41D05744)					
Water (UNII: 059QF0KC	۱ <b>۵</b> D)					
Water (OML 039QF0KC	лок)					
	лок)					
Packaging	Package Description	Marketin	g Start Date	Marketin	ıg End Date	
Packaging # Item Code		Marketin	g Start Date	Marketir	ng End Date	
Packaging   # Item Code   1 NDC:14043-701-20	Package Description	Marketin	g Start Date	Marketir	ng End Date	
Packaging # Item Code 1 NDC:14043-701-20 1	<b>Package Description</b> 1 in 1 CARTON	Marketin	g Start Date	Marketir	ıg End Date	
Item Code     Item Code     NDC:14043-701-20     I   Item Code     I   Item Code   Item Code   Item Code     I   Item Code	<b>Package Description</b> 1 in 1 CARTON 20 mL in 1 VIAL	Marketin	g Start Date	Marketir	ng End Date	
Packaging     Item Code     NDC:14043-701-20     I     NDC:14043-701-50	Package Description1 in 1 CARTON20 mL in 1 VIAL1 in 1 CARTON	Marketin	g Start Date	Marketir	ng End Date	
Packaging     Item Code     NDC:14043-701-20     I     NDC:14043-701-50	Package Description1 in 1 CARTON20 mL in 1 VIAL1 in 1 CARTON	Marketin	g Start Date	Marketin	ıg End Date	
Item Code     Item Code     NDC:14043-701-20     NDC:14043-701-50     NDC:14043-701-50	Package Description1 in 1 CARTON20 mL in 1 VIAL1 in 1 CARTON50 mL in 1 VIAL	Marketin	g Start Date	Marketin	ıg End Date	
Packaging     Item Code     NDC:14043-701-20     NDC:14043-701-50     NDC:14043-701-50     NDC:14043-701-50	Package Description     1 in 1 CARTON     20 mL in 1 VIAL     1 in 1 CARTON     50 mL in 1 VIAL     50 mL in 1 VIAL					
Packaging	Package Description     1 in 1 CARTON     20 mL in 1 VIAL     1 in 1 CARTON     50 mL in 1 VIAL     50 mL in 1 VIAL		g Start Date Marketing Start 09/29/2017		ng End Date	

Labeler - Patterson Veterinary (006962500)

Revised: 9/2017

Patterson Veterinary